Mimedx Group Inc (NASDAQ: MDXG) has a higher price-to-earnings ratio of 22.40x compared to its average ratio. MDXG has 36-month beta value of 1.79. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MDXG is 115.99M, and currently, short sellers hold a 4.47% ratio of that float. The average trading volume of MDXG on June 13, 2025 was 638.12K shares.
MDXG) stock’s latest price update
The stock of Mimedx Group Inc (NASDAQ: MDXG) has decreased by -1.31 when compared to last closing price of 6.12. Despite this, the company has experienced a -6.93% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-27 that MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22 nd Annual Institutional Investor Conference | Minneapolis, MN 1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46 th Annual Global Healthcare Conference | Miami, FL 1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual 1:1 sessions: Wednesday, June 25, 2025 Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.
MDXG’s Market Performance
Mimedx Group Inc (MDXG) has seen a -6.93% fall in stock performance for the week, with a -13.22% decline in the past month and a -23.74% plunge in the past quarter. The volatility ratio for the week is 2.52%, and the volatility levels for the past 30 days are at 2.09% for MDXG. The simple moving average for the past 20 days is -8.19% for MDXG’s stock, with a -19.58% simple moving average for the past 200 days.
Analysts’ Opinion of MDXG
Many brokerage firms have already submitted their reports for MDXG stocks, with Cantor Fitzgerald repeating the rating for MDXG by listing it as a “Overweight.” The predicted price for MDXG in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on July 02, 2024 of the previous year 2024.
Lake Street, on the other hand, stated in their research note that they expect to see MDXG reach a price target of $12. The rating they have provided for MDXG stocks is “Buy” according to the report published on March 07th, 2024.
Craig Hallum gave a rating of “Buy” to MDXG, setting the target price at $12 in the report published on October 27th of the previous year.
MDXG Trading at -10.58% from the 50-Day Moving Average
After a stumble in the market that brought MDXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.43% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MDXG starting from Capper Joseph H, who purchase 200,000 shares at the price of $6.34 back on May 02 ’25. After this action, Capper Joseph H now owns 529,530 shares of Mimedx Group Inc, valued at $1,268,000 using the latest closing price.
Maersk-Moller Kimberly, the Chief Commercial Officer of Mimedx Group Inc, sale 1,759 shares at $8.04 during a trade that took place back on Mar 17 ’25, which means that Maersk-Moller Kimberly is holding 309,077 shares at $14,142 based on the most recent closing price.
Stock Fundamentals for MDXG
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.82 for the gross margin
The net margin for Mimedx Group Inc stands at 0.11. The total capital return value is set at 0.24. Equity return is now at value 22.29, with 16.24 for asset returns.
Based on Mimedx Group Inc (MDXG), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 3.62. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 112.09.
Currently, EBITDA for the company is 64.34 million with net debt to EBITDA at -1.6. When we switch over and look at the enterprise to sales, we see a ratio of 2.28. The receivables turnover for the company is 5.66for trailing twelve months and the total asset turnover is 1.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.70.
Conclusion
To put it simply, Mimedx Group Inc (MDXG) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
